Additionally, in patients with advanced BRAF wild-type melanoma, the concomitance of basal elevated lactate dehydrogenase (LDH) and NLR increasing on treatment with ICIs has been associated with reduced progression-free survival (PFS) [12]. The gene discussed is BRAF; the disease is melanoma.